|
|
Volumn 2, Issue 1, 2005, Pages 47-49
|
|
U.S. regulatory perspective on the minimal clinically important difference in chronic obstructive pulmonary disease
|
|
Author keywords
Clinical trials; COPD; Drug; Endpoints; Regulation; Viewpoint
|
|
Indexed keywords
BETA ADRENERGIC RECEPTOR STIMULATING AGENT;
BRONCHODILATING AGENT;
CHOLINERGIC RECEPTOR BLOCKING AGENT;
CORTICOSTEROID;
FLUTICASONE PROPIONATE;
FORMOTEROL FUMARATE;
IPRATROPIUM BROMIDE;
SALBUTAMOL;
SALMETEROL XINAFOATE;
TIOTROPIUM BROMIDE;
CHRONIC OBSTRUCTIVE LUNG DISEASE;
CONFERENCE PAPER;
DRUG APPROVAL;
EXPERIENCE;
HUMAN;
MINIMAL CLINICALLY IMPORTANT DIFFERENCE;
OUTCOMES RESEARCH;
PRIORITY JOURNAL;
REGULATORY MECHANISM;
STATISTICAL ANALYSIS;
STATISTICAL MODEL;
STATISTICS;
UNITED STATES;
CLINICAL TRIALS;
CLINICAL TRIALS AS TOPIC;
DATA INTERPRETATION, STATISTICAL;
FORCED EXPIRATORY VOLUME;
HUMANS;
OUTCOME ASSESSMENT (HEALTH CARE);
PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;
TREATMENT OUTCOME;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 20144384260
PISSN: 15412555
EISSN: 15412563
Source Type: Journal
DOI: 10.1081/COPD-200050660 Document Type: Conference Paper |
|
Times cited : (10)
|
|
References (1)
|
